B7H2-Fc-trastuzumab

**B7H2-Fc-trastuzumab** is an experimental recombinant fusion protein designed for the treatment of HER2-positive malignancies. It consists of the extracellular domain of the **inducible T-cell co-stimulator ligand** (B7H2 or ICOSL) fused to the Fc region of the monoclonal antibody **trastuzumab**. The molecule operates through a dual mechanism of action: the trastuzumab component targets and inhibits the **Human Epidermal Growth Factor Receptor 2 (HER2)** on tumor cells, while the B7H2 component acts as an agonist for the **Inducible T-cell Co-stimulator (ICOS)** receptor on T-cells. This co-stimulation is intended to enhance T-cell activation, proliferation, and cytokine production within the tumor microenvironment, potentially overcoming resistance to standard HER2-targeted therapies. Additionally, the Fc portion of the fusion protein can mediate antibody-dependent cellular cytotoxicity (ADCC). Developed primarily in a research context by UTHealth in collaboration with MedImmune, it has shown potent antitumor activity in preclinical models of breast and gastric cancers.

Other names

B7-H2-Fc-trastuzumabB-7-H2-Fc-trastuzumabB 7-H2-Fc-trastuzumabtrastuzumab-ICOSL fusion proteinB7H2-Fc-HerceptinB-7H2-Fc-HerceptinB 7H2-Fc-HerceptinICOSL-Fc-trastuzumab